Siponimod, a new selective modulator of S1PR1 and S1PR5 with a short half-life and a better safety profile, has gained considerable attention as an immunomodulatory agent for the treatment of ischemic or hemorrhagic stroke in animals [16, 36, 37]. Here, S1PR1 is linked to hemorrhagic stroke.